ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer’s Association International Conference (AAIC-2017)

24 July 2017 BARCELONA, SPAIN and CAMBRIDGE MA. • Excellent safety data profile on 106 healthy volunteers • The molecule is brain penetrant • Data allows establishment of a safe administration scheme for long term efficacy studies Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented last week final data on the First in Human clinical trial of ORY-2001 at the Alzheimer’s Association International Conference (AAIC-2017), which took place from 16 to 20 July in London (United Kingdom). Oryzon’s communication, on poster session S8, was entitled “First-in-Human Phase I Results Show Safety, Tolerability and Brain Penetrance of ORY-2001, an Epigenetic Drug Targeting LSD1 and MAO-B” and was presented by Dr. Tamara Maes, Chief Scientific Officer, and Dr. Roger Bullock, Chief Medical Officer of the company. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗